A Mycophenolate Pharmacokinetic Study with New Insights into Enterohepatic Recirculation in Kidney Transplant Recipients
Clinical Pharmacokinetics · 2026-03 · 65 (3) · 479-495
DOI: 10.1007/s40262-025-01611-3 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 06.02.2026. Verfasst von Moataz E Mohamed und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, 7-151 Weaver-Densford Hall, 308 Harvard Street SE…. Hauptthemen laut MEDLINE: Enterohepatic Circulation, Immunosuppressive Agents, Kidney Transplantation, Mycophenolic Acid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NCATS NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
BACKGROUND: Mycophenolic acid (MPA) has complex pharmacokinetics in part due to enterohepatic recirculation (EHR). A deeper understanding of MPA pharmacokinetics and specifically how EHR and patterns of EHR affect exposure will improve immunosuppression outcomes. This study provides a contemporary and comprehensive assessment of MPA and metabolites in the blood and urine with a focus on EHR characteristics. METHODS: Kidney transplant recipients (n = 84) receiving mycophenolate mofetil (MMF) and tacrolimus underwent an intensive MPA pharmacokinetic assessment. Pharmacokinetics of MPA and its metabolites, EHR%, and number of secondary peaks were determined. The associations between EHR, the number of secondary peaks, and achievement of MPA therapeutic range were studied. MMF dose proportionality with MPA exposure was evaluated. RESULTS: MPA exhibited high pharmacokinetic variability, with 5.5-fold differences in AUC0-12, 18.4-fold differences in trough concentrations, and a 3.4-fold difference in EHR%. Median MPA EHR% was 40.5%. There were no significant associations between EHR% and MPA AUC0-12 or trough. MPA AUC0-12 and trough were significantly associated with the number of MPA secondary peaks (0, 1, or ≥ 2 peaks). Participants without secondary peaks showed the highest percentage of subtherapeutic MPA AUC0-12 and troughs, while participants with ≥ 2 peaks were more likely to be supratherapeutic. CONCLUSIONS: There was no association between the EHR% and MPA AUC0-12 or trough. We identified three distinct patterns of MPA secondary peaks (0, 1, or ≥ 2 peaks), which were significantly associated with MPA AUC0-12 and trough. Studies to evaluate the relationship of MPA EHR measures and clinical outcomes are needed. TRIAL REGISTRY: Clinical Trial Notation: clinicaltrials.gov, NCT04953715.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, 7-151 Weaver-Densford Hall, 308 Harvard Street SE, Minneapolis, MN, 55455, USA.
- Division of Nephrology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
- Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA.
- Department of Surgery, School of Medicine, University of Minnesota, Minneapolis, MN, 55455, USA.
- Division of Nephrology and Hypertension, School of Medicine, University of Minnesota, Minneapolis, MN, 55455, USA.
- Department of Food Science and Nutrition, University of Minnesota, St. Paul, MN, 55108, USA.
ORCID-Profile: Moataz E Mohamed, Abdelrahman Saqr, Guillaume Onyeaghala, Rory P Remmel, Christopher Staley, Casey R Dorr, Levi Teigen, Weihua Guan, Rasha El-Rifai, William S Oetting, Arthur J Matas, Ajay K Israni, Pamala A Jacobson
Förderung
- NIAID NIH HHS
- NCATS NIH HHS
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Zitieren
APA
Mohamed, M. E., Saqr, A., Onyeaghala, G., Remmel, R. P., Staley, C., Dorr, C. R., Teigen, L., Guan, W., Vo, D., El-Rifai, R., Oetting, W. S., Matas, A. J., Israni, A. K., & Jacobson, P. A. (2026). A Mycophenolate Pharmacokinetic Study with New Insights into Enterohepatic Recirculation in Kidney Transplant Recipients. Clinical Pharmacokinetics, 65(3), 479-495. https://doi.org/10.1007/s40262-025-01611-3
Vancouver
Mohamed ME, Saqr A, Onyeaghala G, Remmel RP, Staley C, Dorr CR, et al. A Mycophenolate Pharmacokinetic Study with New Insights into Enterohepatic Recirculation in Kidney Transplant Recipients. Clinical Pharmacokinetics. 2026;65(3):479-495. doi:10.1007/s40262-025-01611-3
BibTeX
@article{Mohamed2026,
author = {Mohamed, Moataz E and Saqr, Abdelrahman and Onyeaghala, Guillaume and Remmel, Rory P and Staley, Christopher and Dorr, Casey R and Teigen, Levi and Guan, Weihua and Vo, Duy and El-Rifai, Rasha and Oetting, William S and Matas, Arthur J and Israni, Ajay K and Jacobson, Pamala A},
title = {A Mycophenolate Pharmacokinetic Study with New Insights into Enterohepatic Recirculation in Kidney Transplant Recipients},
journal = {Clinical Pharmacokinetics},
year = {2026},
volume = {65},
number = {3},
pages = {479--495},
doi = {10.1007/s40262-025-01611-3}
}
EUVIMED